• 

  FabiSpray -- India's first nasal spray for treating adult COVID-19 patients launched

  India | February 09, 2022 11:44 IST

  Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart said "we are confident it will offer patients a much needed and timely therapy option."

• 

  Glenmark Life Sciences IPO Listing today, GMP indicated moderate listing gain

  August 06, 2021 8:03 IST

  Glenmark Life Sciences IPO Listing Date, Glenmark Life Sciences Share Price: Glenmark Life Sciences IPO GMP is currently at Rs 85.

• 

  Glenmark Life Sciences IPO GMP falling, Why?

  August 02, 2021 10:40 IST

  Glenmark IPO Allotment Date, Glenmark Life Sciences IPO GMP: Glenmark Life Sciences is a subsidiary of Glenmark Pharmaceuticals. Glenmark Life Sciences IPO listing date is August 6.

• 

  Glenmark Life Sciences IPO: Subscription begins today, Check price band, GMP and more

  July 27, 2021 10:24 IST

  Glenmark Life Sciences IPO, Glenmark Life Sciences GMP: Glenmark Life Sciences IPO is open for subscription. The grey market premium is currently at 20 per cent premium. 

• 

  Glenmark Life Sciences mobilises Rs 454 crore from anchor investors ahead of IPO

  Business | July 26, 2021 22:13 IST

  Glenmark Life Sciences IPO: ​Glenmark Life Sciences on Monday said it has raised Rs 454 crore from anchor investors ahead of its initial share sale, which opens for public subscription on Tuesday.

• 

  Glenmark Life Sciences IPO to open for subscription on July 27. Check details

  Business | July 20, 2021 16:02 IST

  Glenmark Life Sciences IPO: ​The initial public offer (IPO) of Glenmark Life Sciences will open for subscription on July 27 and close on July 29, 2021. Glenmark Life Sciences is the API (active pharmaceutical ingredients) arm of Glenmark Pharmaceuticals.

• 

  Glenmark Pharma gets tentative nod from USFDA for anticoagulant drug

  World | December 21, 2020 11:56 IST

  Drug major Glenmark Pharma on Monday said it has received tentative approval from the US health regulator for anticoagulant Dabigatran Etexilate capsules.

• 

  Glenmark releases phase-3 trial data of Favipiravir, says 40% faster 'clinical cure' witnessed

  Fyi | July 22, 2020 22:47 IST

  According to Glenmark, 40 per cent faster achievement of "clinical cure" was witnessed in the third phase of the clinical trials of Favipiravir involving 150 patients with mild to moderate COVID-19 across seven clinical sites in India.

• 

  FabiFlu more economical, effective treatment option for COVID-19: Glenmark

  Business | July 21, 2020 14:47 IST

  Glenmark Pharmaceuticals on Tuesday said its generic version of antiviral drug Favipiravir, FabiFlu, is more economical and effective than other drugs available in the market approved for emergency use for treatment of COVID-19. 

• 

  DCGI sends notice to Glenmark for false claims, overpricing of COVID-19 drug FabiFlu

  India | July 19, 2020 22:11 IST

  The Drug Controller General of India (DCGI) issued notices to Glenmark seeking clarification from the company regarding the false claim that its antiviral drug Fabiflu, is effective on COVID-19 patients with co-morbidities.

• 

  Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID-19 fight, say medical experts

  India | June 22, 2020 23:06 IST

  With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".

Advertisement
• 

  Glenmark launches COVID-19 drug after DCGI nod

  Business | June 20, 2020 21:02 IST

  Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.

• 

  Glenmark begins phase 3 of clinical trials on antiviral Favipiravir for COVID-19 patients in India

  Science | May 12, 2020 12:10 IST

  Glenmark has successfully developed the active pharma ingredient (API) and the formulations for the product through its in-house R&D team. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.

• 

  Lifting ban on FDC drugs against patients' safety: Centre

  India | March 21, 2016 22:15 IST

  The government on Monday sought vacation of Delhi High Court's interim order staying the ban on some fixed dose combinations (FDC) medicines, saying it would be "against public interest and patient safety"

• 

  Over generic filing on cardiac drug Sanofi sues Glenmark

  March 06, 2014 18:31 IST

  Mumbai: Glenmark Pharmaceuticals Ltd has been sued by Sanofi, SA, in a US court after the Indian company filed an application with the US Food and Drug Administration (FDA). According to FDA, the company seeks

• 

  UCB files cases against Ranbaxy, Aurobindo, Glenmark, Sun Pharma, others on patent issue

  July 22, 2013 18:06 IST

  Hyderabad, July 22: UCB, a global biopharma company, alongwith others has filed separate cases against as many as 15 drug makers, including India's Ranbaxy, Aurobindo, Zydus, Sun Pharma, Glenmark and Alembic Pharmaceuticals for allegedly infringing